Adelaide Research & Scholarship: Search

Search

Search:
for

Current filters:

Start a new search

Add filters:

Results/Page | Sort items by In order Authors/record

Results 11-20 of 29 (Search time: 0.005 seconds).

Item hits:

Preview	Issue Date	Title	Author(s)
	2003	Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors	Dewar, A.; Domaschenz, R.; Doherty, K.; Hughes, T.; Lyons, A.
	2003	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia	Hughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
	2010	Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia	Saglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
	2004	Clinical resistance to imatinib: mechanisms and implications	Hochhaus, A.; Hughes, T.
	2009	Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase	Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
	2009	Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?	Branford, S.; Vaz de Melo, J.; Hughes, T.
	2012	BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management	Branford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
	2005	In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.	White, D.; Saunders, V.; Lyons, A.; Branford, S.; Grigg, A.; To, L.; Hughes, T.
	2011	Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy	Parker, W.; Lawrence, R.; Ho, M.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.
	2012	Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response	White, D.; Hughes, T.